Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]Zr-DFO*-NCS-Abeta-mAb-scFab8D3
- Development stage
- Preclinical
- Lead developer
- Amsterdam UMC
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[89Zr]Zr-DFO*-NCS-Abeta-mAb-scFab8D3 (also known as [89Zr]Zr-DFO*-NCS-Adu-8D3) is a preclinical radiolabeled bispecific monoclonal antibody conjugate developed by Amsterdam UMC and Lundbeck for positron emission tomography (PET) imaging of amyloid-beta (Aβ) pathology in Alzheimer's disease. The agent consists of an aducanumab-derived antibody targeting Aβ, fused to a single-chain Fab fragment of the 8D3 antibody targeting transferrin receptor 1 (TfR1) to facilitate receptor-mediated transcytosis across the blood-brain barrier (BBB). It is conjugated with the novel bifunctional chelator DFO*-NCS and radiolabeled with the positron emitter zirconium-89 (89Zr). Preclinical studies have demonstrated that the use of the DFO* chelator provides superior stability and high, specific brain uptake, enabling the early detection of Aβ plaque pathology and the quantification of antibody brain delivery.
- Other names
- [89Zr]Zr-DFO*-Adu-8D3[89Zr]Zr-DFO*-NCS-Adu-8D3[89Zr]Zr-DFO*-NCS-mAbAdu-scFab8D3[89Zr]Zr-DFO*-mAbAdu-scFab8D3
02
Targets
Aβ (Amyloid-beta peptides and aggregates)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on [89Zr]Zr-DFO*-NCS-Abeta-mAb-scFab8D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [89Zr]Zr-DFO*-NCS-Abeta-mAb-scFab8D3.